Depression and Antidepressant Development
Ketabon GmbH focuses on depression research through clinical work centred on ketamine-based antidepressant strategies, with interest in treatments designed to address mood disorders.
- Ketamine hydrochloride
- Esketamine
- Mood disorder therapeutics
The sponsor’s research activity is directed toward orally administered ketamine formulations and comparative evaluation against established intranasal esketamine in the context of antidepressant treatment.
Central Nervous System Safety and Tolerability
The clinical focus includes central nervous system effects relevant to treatment tolerability, with attention to dissociative symptoms and overall safety in relation to ketamine-derived therapies.
- Dissociation
- Neuropsychiatric safety
- Tolerability assessment
Research interest extends to how ketamine formulations are tolerated in human subjects and how treatment-related neuropsychiatric effects are characterised.
Pharmacokinetics of Oral Ketamine Formulations
Ketabon GmbH is involved in the study of pharmacokinetics for oral ketamine products, with emphasis on how prolonged-release formulations behave in the body.
- Oral prolonged-release tablets
- Drug exposure
- Comparative pharmacology
This area reflects an interest in the clinical development of ketamine delivery systems intended for psychiatric use.
Healthy Volunteer Clinical Evaluation
The sponsor’s funded research includes testing in healthy male subjects, supporting early clinical assessment of tolerability, safety, and treatment-related response profiles.
- Healthy volunteer studies
- Single-dose evaluation
- Comparative clinical assessment
These investigations support the clinical characterisation of ketamine-based therapies before broader use in psychiatric indications.
